FindTrial
Sign In

FT596

DRUG3 trials

Sponsors

Fate Therapeutics, Masonic Cancer Center, University of Minnesota

Conditions

Chronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaFollicular LymphomaHigh-grade B-cell LymphomaLymphoma, B-CellMantle Cell LymphomaMarginal Zone LymphomaNHL

Phase 1

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
TerminatedNCT04245722
Fate TherapeuticsChronic Lymphocytic Leukemia, Lymphoma, B-Cell
Start: 2020-03-19End: 2023-09-27Updated: 2023-10-26
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
CompletedNCT04555811
Masonic Cancer Center, University of MinnesotaDiffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, NHL +1
Start: 2020-09-22End: 2023-11-30Updated: 2024-07-09
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
WithdrawnNCT05934097
Fate TherapeuticsDiffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma +2
Start: 2022-12-31End: 2039-05-31Updated: 2023-07-06

Related Papers

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial.
2025-01-0156 citations
Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma
Blood2021-11-0577 citations
Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells
Blood2021-11-059 citations
Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma
Blood2020-11-0436 citations